In a study of 288 women from 2001, the drug tamoxifen reduced breast-cancer incidence among healthy BRCA2 carriers by 62% compared with a placebo, though it didn't reduce breast-cancer incidence among healthy women with BRCA1 mutations.
Carriers will resell the data in healthy doses of 1GB or larger, and Avanti is adamant that there won't be any nasty throttling surprises waiting in store.
It seems as if there are signs of life in the telecommunications industry at last, a healthy wave of mergers that will bring about a new breed of smarter, streamlined carriers.